Ardelyx Inc (NASDAQ:ARDX) has coverage initiated with a Buy rating

Analyst Ratings For Ardelyx Inc (NASDAQ:ARDX)

Story continues below

Today, Jefferies Financial Group initiated coverage on Ardelyx Inc (NASDAQ:ARDX) with a Buy.

There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Ardelyx Inc (NASDAQ:ARDX) is Buy with a consensus target price of $12.80 per share, a potential 208.43% upside.

Some recent analyst ratings include

  • 8/24/2018-Ardelyx Inc (NASDAQ:ARDX) has coverage initiated with a Buy rating
  • 3/19/2018-Ardelyx Inc (NASDAQ:ARDX) had its Outperform ➝ Outperform rating reiterated by Leerink Swann with a $13.00 price target
  • 3/15/2018-Ardelyx Inc (NASDAQ:ARDX) had its Outperform rating reiterated by Wedbush

Recent Insider Trading Activity For Ardelyx Inc (NASDAQ:ARDX)
Ardelyx Inc (NASDAQ:ARDX) has insider ownership of 16.60% and institutional ownership of 81.75%.

  • On 5/30/2018 Gordon Ringold, Director, bought 10,000 with an average share price of $4.00 per share and the total transaction amounting to $40,000.00.
  • On 10/24/2017 Reginald Seeto, COO, sold 10,008 with an average share price of $5.20 per share and the total transaction amounting to $52,041.60.
  • On 8/30/2017 Forest Baskett, Major Shareholder, sold 485 with an average share price of $4.95 per share and the total transaction amounting to $2,400.75.
  • On 4/18/2017 David P. Rosenbaum, Insider, sold 2,051 with an average share price of $11.98 per share and the total transaction amounting to $24,570.98.
  • On 3/3/2017 Jeremy S. Caldwell, EVP, sold 1,026 with an average share price of $14.14 per share and the total transaction amounting to $14,507.64.
  • On 12/16/2016 David P Rosenbaum, SVP, sold 900 with an average share price of $14.48 per share and the total transaction amounting to $13,032.00.
  • On 10/11/2016 Jeffrey W. Jacobs, SVP, sold 6,000 with an average share price of $15.00 per share and the total transaction amounting to $90,000.00.

About Ardelyx Inc (NASDAQ:ARDX)
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Recent Trading Activity for Ardelyx Inc (NASDAQ:ARDX)
Shares of Ardelyx Inc closed the previous trading session at 4.15 −0.050 1.19% with 4.3 shares trading hands.

An ad to help with our costs